MedPath

Holy Stone Healthcare Co., Ltd.

Holy Stone Healthcare Co., Ltd. logo
🇹🇼Taiwan
Ownership
Public
Established
2001-01-01
Employees
1K
Market Cap
-
Website
http://www.hshc.com.tw

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Phase 2
Not yet recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
Biological: Bevacizumab
First Posted Date
2023-09-15
Last Posted Date
2023-09-15
Lead Sponsor
Holy Stone Healthcare Co., Ltd
Target Recruit Count
100
Registration Number
NCT06039202

Individual Patient Expanded Access to CA102N

Conditions
Advanced or Metastatic Colorectal Cancer (mCRC)
First Posted Date
2022-03-10
Last Posted Date
2023-02-27
Lead Sponsor
Holy Stone Healthcare Co., Ltd
Registration Number
NCT05274204

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced or Metastatic Colorectal Cancer (mCRC)
Advanced or Metastatic Solid Tumors
Interventions
First Posted Date
2018-08-06
Last Posted Date
2022-09-21
Lead Sponsor
Holy Stone Healthcare Co., Ltd
Target Recruit Count
37
Registration Number
NCT03616574
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M

Phase 2
Completed
Conditions
Colitis, Ulcerative
Interventions
Drug: Placebo
Drug: Low dose
Drug: High dose
First Posted Date
2015-07-09
Last Posted Date
2021-10-26
Lead Sponsor
Holy Stone Healthcare Co., Ltd
Target Recruit Count
51
Registration Number
NCT02493712
Locations
🇮🇹

Istituto Clinico Humanitas, Milan, Italy

Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: IBD98-M without HA
First Posted Date
2014-07-22
Last Posted Date
2015-04-22
Lead Sponsor
Holy Stone Healthcare Co., Ltd
Target Recruit Count
30
Registration Number
NCT02196662
Locations
🇨🇦

inVentiv Health Clinique, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath